- Home
- RZLT vs PRTA Comparison
RZLT vs PRTA Comparison
Compare RZLT & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RZLT
- PRTA
- Stock Information
- Founded
- RZLT 2010
- PRTA 2012
- Country
- RZLT United States
- PRTA Ireland
- Employees
- RZLT N/A
- PRTA N/A
- Industry
- RZLT Biotechnology: Pharmaceutical Preparations
- PRTA Biotechnology: Pharmaceutical Preparations
- Sector
- RZLT Health Care
- PRTA Health Care
- Exchange
- RZLT Nasdaq
- PRTA Nasdaq
- Market Cap
- RZLT 361.3M
- PRTA 346.4M
- IPO Year
- RZLT N/A
- PRTA N/A
- Fundamental
- Price
- RZLT $5.26
- PRTA $6.41
- Analyst Decision
- RZLT Strong Buy
- PRTA Buy
- Analyst Count
- RZLT 6
- PRTA 9
- Target Price
- RZLT $12.00
- PRTA $27.67
- AVG Volume (30 Days)
- RZLT 1.4M
- PRTA 1.7M
- Earning Date
- RZLT 05-13-2025
- PRTA 08-07-2025
- Dividend Yield
- RZLT N/A
- PRTA N/A
- EPS Growth
- RZLT N/A
- PRTA N/A
- EPS
- RZLT N/A
- PRTA N/A
- Revenue
- RZLT N/A
- PRTA $137,935,000.00
- Revenue This Year
- RZLT $35.39
- PRTA N/A
- Revenue Next Year
- RZLT N/A
- PRTA $122.02
- P/E Ratio
- RZLT N/A
- PRTA N/A
- Revenue Growth
- RZLT N/A
- PRTA 54.55
- 52 Week Low
- RZLT $2.22
- PRTA $4.32
- 52 Week High
- RZLT $6.19
- PRTA $25.42
- Technical
- Relative Strength Index (RSI)
- RZLT 74.51
- PRTA 57.61
- Support Level
- RZLT $4.15
- PRTA $5.96
- Resistance Level
- RZLT $5.39
- PRTA $6.77
- Average True Range (ATR)
- RZLT 0.30
- PRTA 0.36
- MACD
- RZLT 0.08
- PRTA 0.14
- Stochastic Oscillator
- RZLT 90.85
- PRTA 75.80
About RZLT Rezolute Inc. (NV)
Rezolute Inc is a biopharmaceutical company. The company develops novel, sustained-release injectable therapies. It applies proprietary formulation and manufacturing capabilities to known, well-characterized molecules to create differentiated, patent-protected therapies that have the potential to significantly improve existing standards of care. Its pipeline products include RZ358 and RZ402.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.